|
5 Companies Leading the Fight Against Multiple Sclerosis
Motley Fool Perhaps the most exciting of the bunch, in my opinion as least, is daclizumab, which is being co-developed with AbbVie and is being tested as a relapse-remitting MS therapy that’s injected just once every four weeks. Daclizumab itself is a humanized … |
Antibodies against gonadotropin-releasing hormone (GnRH) in patients with …7thSpace Interactive (press release)The aim of the present study was to scrutinize patients with diabetes mellitus with regard to the presence of GnRH antibodies, and to exami…
New Vasculitis Treatment As Good As Standard TherapyArthritis TodayFour weekly infusions of the biologic drug rituximab (Rituxan) work just as well to control a type of vasculitis as the current standard of care that involves 18 months of daily immunos…
Rituximab safely treated RA patients in long-term follow-upHealioThere were 3,194 patients (mean age, 51.5 years; 80.8% women) who had been treated with a maximum of 17 courses of rituximab plus methotrexate (MTX) for up to 9.5 years (all exposure pati…
|
Biosimilar Opportunities in an Evolving Market
KLFY In terms of revenue, six of the top ten pharmaceutical therapies are biological products, which have been targeted by biosimilar developers: Abbvie’s Humira (adalimumab), Roche’s MabThera (rituximab), Herceptin (trastuzumab) and Avastin (bevacizumab), … |
OncLiveIbrutinib Combo Achieves 100% Response Rate in Patients With NHLOncLiveAdding ibrutinib to standard rituximab (R)-CHOP chemotherapy for non-Hodgkin lymphoma (NHL) resulted in an objective response rate of 100%, according to the results of a smal…
|
Biosimilar Opportunities in an Evolving Market
Sacramento Bee In terms of revenue, six of the top ten pharmaceutical therapies are biological products, which have been targeted by biosimilar developers: Abbvie’s Humira (adalimumab), Roche’s MabThera (rituximab), Herceptin (trastuzumab) and Avastin (bevacizumab), … |
|
Bavituximab’s Mechanism of Action Highlighted at Immunomodulatory …
Marketwire (press release) TUSTIN, CA–(Marketwired – Aug 14, 2013) – Peregrine Pharmaceuticals, Inc. ( NASDAQ : PPHM) today announced the presentation of preclinical data and ongoing drug development activities highlighting the immune-stimulatory mechanism of action of … |
|
Neutralizing Antibodies Key to Broad Anti-Flu Immunity
Genetic Engineering News Writing in the August 14th issue of Science Translational Medicine, scientists at the Icahn School of Medicine at Mount Sinai described how exposure to seasonal flu viruses over the course of a lifetime influences a person’s antibody repertoire and … |
Epratuzumab and Rituximab Produce High Rate and Durable Progression-Free …NASDAQMORRIS PLAINS, N.J., Aug. 14, 2013 (GLOBE NEWSWIRE) –Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal ant…